3920.F Spyre Therapeutics, Inc.
- Market cap
- EUR 8.83B
- P/E
- -
- P/B
- 10.70x
- ROE
- -25.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 3920.F undervalued?
Graham numberThe Graham number of Spyre Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Spyre Therapeutics, Inc. fundamental analysis
No fundamental analysis for Spyre Therapeutics, Inc. yet.
Spyre Therapeutics, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 " anti-TL1A mAbs designed to…
Full company profileSpyre Therapeutics, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Spyre Therapeutics, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 18.7M | 2.33M | 886K | 0.00 | 0.00 | 0.00 |
| Operating Income | -65.6M | -84.8M | -129M | -209M | -220M | -351M |
| EBITDA | - | -82.8M | -128M | -209M | -220M | -351M |
| Net Income | -65.8M | -83.8M | -339M | -208M | -155M | -268M |
| EPS | -33 | -32 | -9.40 | -3.45 | -1.98 | -2.87 |
| Balance Sheet | ||||||
| Total Assets | 110M | 71.1M | 342M | 608M | 778M | 1.10B |
| Total Liabilities | 26.0M | 20.8M | 158M | 90.7M | 62.5M | 48.2M |
| Shareholders' Equity | 83.9M | 50.3M | 184M | 518M | 715M | 1.05B |
| Cash & Short-term Investments | 15.1M | 34.9M | 189M | 89.4M | 85.7M | 82.7M |
| Cash Flow | ||||||
| Operating Cash Flow | -53.7M | -80.1M | -99.9M | -157M | -169M | -273M |
| Capital Expenditure | 573K | 38.0K | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -54.3M | -80.2M | -99.9M | -157M | -169M | -273M |
| Ratios | ||||||
| ROE | -78.4% | -166.6% | -184.1% | -40.2% | -21.7% | -25.5% |
| ROA | -59.9% | -117.8% | -99.1% | -34.2% | -20.0% | -24.4% |
| Net Profit Margin | -351.1% | -3,598.8% | -38,238.1% | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Spyre Therapeutics, Inc. dividends
Spyre Therapeutics, Inc. has not paid dividends in the last 5 fiscal years.
Who owns Spyre Therapeutics, Inc.
- Insiders 1.54%
- Institutions 98.46%
- Public & others 0.00%
- Shares outstanding 95.0M
- Free float 89.0M
Spyre Therapeutics, Inc. company profile
- Company name
- Spyre Therapeutics, Inc.
- Ticker
- 3920.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 130
- Fiscal year end
- December
- Address
- Building 23, Waltham, MA, United States, 02453
- Phone
- 617 651 5940
- Website
- spyre.com
About Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 " anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Spyre Therapeutics, Inc. management
10- Dr. Cameron Turtle DPHIL, Ph.D.CEO & Director · born 1990
- Mr. Scott L. BurrowsChief Financial Officer · born 1977
- Ms. Heidy Abreu King-Jones J.D., L.L.M.Chief Legal Officer & Corporate Secretary · born 1983
- Dr. Sheldon Sloan M.B.E., M.D.Chief Medical Officer · born 1959
- Dr. Janet Gunzner-Toste M.B.A., Ph.D.Senior Vice President of Operations
- Mr. Brian ConnollyChief Technical Officer
- Mr. Eric McIntyreSenior Vice President of Finance & Investor Relations
- Mr. James MyersSenior Vice President of Quality & Compliance
- Dr. Justin LaFountaine Ph.D.Senior Vice President of Corporate Development
- Ms. Melissa CooperSenior Vice President of People